Pharma News
22 Jun 2025 to 28 Jun 2025
Jun 28, 2025
Novo Nordisk (NVO) Teams Up with WeightWatchers Following Hims & Hers Disagreement
Novo Nordisk (NVO) has partnered with WeightWatchers to enhance access to its weight-loss drug Wegovy, following issues with Hims & Hers over alleged illegal sales of Wegovy copies. The collaboration starts July 1, alongside a new cash-offer price of $299 for Wegovy. Novo Nordisk is also pursuing legal action against knockoff drug sellers.
Jun 28, 2025
Gilead's Patent Case: What Biotech Investors Need to Know About Upcoming Risks
Recent legal challenges involving Gilead Sciences (NASDAQ: GILD) have raised concerns about the stability of patent protections in the biotech sector. A landmark case against the U.S. government invalidated key patents for Gilead's HIV drugs, potentially reshaping investment strategies. Investors are urged to reassess exposure to patent-dependent firms as generic competition and stricter patent laws threaten future profits.
Jun 27, 2025
Health Update: Novo Nordisk's semaglutide could benefit certain individuals with type 1 diabetes.
A small trial indicates that semaglutide, a GLP-1 drug from Novo Nordisk, may aid weight loss and blood sugar control in type 1 diabetes patients. Participants receiving semaglutide lost an average of 20 pounds and spent more time in their target blood sugar range compared to those on placebo. Researchers advocate for further studies to seek regulatory approval for its use in type 1 diabetes management.
Jun 27, 2025
Amgen Aims to Capture Market Share in Growing Obesity Sector: Can It Achieve Success? - TradingView
Amgen (AMGN) is developing MariTide, a GIPR/GLP-1 receptor drug for obesity, aiming for a single monthly dose. In phase II studies, it showed up to 20% weight loss over 52 weeks. Amgen has initiated phase III trials and is also exploring another candidate, AMG 513. The obesity drug market is projected to reach $100 billion by 2030.
Jun 27, 2025
Biosimilars Market Projected to Grow at a 19.4% CAGR in the Coming Five Years
A recent BCC Research report forecasts the global biosimilars market will grow from $28.5 billion in 2024 to $69.2 billion by 2029, with a CAGR of 19.4%. Key drivers include patent expirations of major biologics, cost-effectiveness, and increased awareness. Leading companies in the sector include Amgen Inc., Pfizer Inc., and Biocon Biologics Ltd.
Jun 27, 2025
Reasons Behind Today's Surge in Stock for Weight Loss Pharmaceutical Company
Viking Therapeutics (NASDAQ: VKTX) shares rose 6.3% following the initiation of a phase 3 trial for VK2375, a dual GLP-1/GIP receptor agonist aimed at treating metabolic disorders like obesity. The company is also developing an oral formulation, with phase 2 results expected later this year. Competition includes Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
Jun 27, 2025
AbbVie Increases Value by Over $24 Billion in Half a Year: Strategies for Investing in ABBV Stock - The Globe and Mail
AbbVie (ABBV) stock has risen 8% in six months, adding over $24 billion to its market value. The company successfully transitioned from the loss of Humira's exclusivity to strong sales from new drugs Skyrizi and Rinvoq, which generated $5.1 billion in Q1 2025. Despite challenges from Humira biosimilars and declining aesthetics sales, AbbVie expects robust growth driven by its pipeline and new product launches.
Jun 26, 2025
UK Court of Appeal reverses decision to deny temporary injunction against generic manufacturers.
In a pivotal ruling, the Court of Appeal granted AstraZeneca an interim injunction against Glenmark Pharmaceuticals, preventing the launch of its generic dapagliflozin, marketed as Forxiga. Despite the High Court's invalidation of AstraZeneca's patent, the Court emphasized the need to maintain the status quo amid concerns over potential irreversible price erosion from multiple generic entries. The case highlights the importance of "clearing the path" before launching generics.
Jun 26, 2025
'It's Time for Major Players': Punjab Chief Minister Bhagwant Mann Suggests Action Against Drug Lords Following...
Punjab Chief Minister Bhagwant Mann announced that major drug kingpins, referred to as 'Jarnails', will face consequences for their involvement in the drug trade following the arrest of Shiromani Akali Dal's Bikram Singh Majithia. Mann emphasized the collection of substantial evidence, including records of hawala transactions, and vowed to investigate all links in the drug money chain.
Jun 26, 2025
Lilly set to introduce Mounjaro pen in India as competition with Novo intensifies in the large market - TradingView
India's drug regulator has approved Eli Lilly's pre-filled injector pens for its weight-loss drug, Mounjaro, enhancing competition against Novo Nordisk's Wegovy. Mounjaro is available in six dose strengths, while several Indian companies, including Sun Pharma, Biocon, and Cipla, are developing their own GLP-1 treatments to enter the growing obesity market.
Jun 26, 2025
Novo Nordisk partners with WeightWatchers to market Wegovy - TradingView
Novo Nordisk announced a collaboration with WeightWatchers to market its weight-loss drug, Wegovy, beginning July 1. This partnership aims to enhance the accessibility and promotion of the blockbuster medication.
Jun 26, 2025
Cigna Reports That Bristol-Myers Has Postponed Generic Version of Cancer Medication - Law360 Healthcare Authority
Cigna has filed an antitrust lawsuit in New York against Bristol-Myers Squibb Co. and its subsidiary Celgene, alleging that they fraudulently obtained patents and engaged in sham litigation to delay the release of a generic cancer drug.
Jun 26, 2025
The leading 10 medications based on patent numbers: The rise of biologics in creating 'platform empires' compared to small molecules...
Roche's Herceptin (trastuzumab) has 1,536 patents, highlighting a strategic shift in pharmaceutical patenting, particularly for biologics. This contrasts with only 393 patents found in title-only searches. The data reveals a focus on expanding indications and combination therapies, with significant patent activity continuing decades after its 1998 approval. Other drugs like Eliquis (apixaban) and Xarelto (rivaroxaban) follow a different patenting strategy.
Jun 26, 2025
Examining significant trends in China's patent-linkage framework and their effects on the pharmaceutical industry...
China's evolving pharmaceutical landscape is marked by significant changes in its patent linkage system, aimed at fostering innovation. Since 2021, new laws on patent term adjustments and data exclusivity have been introduced. The system allows originator drug patent listings, impacting generic drug approvals. Key differences from the US system include notification obligations and waiting periods, influencing patent strategies for companies operating in China.
Jun 26, 2025
Eli Lilly's Mounjaro KwikPen for diabetes receives approval from regulators in India - CNBC TV18
Eli Lilly and Company's obesity and Type 2 diabetes drug, Mounjaro (tirzepatide), has received approval from India's Central Drugs Standard Control Organisation for its KwikPen presentation. The multi-dose pen will offer six dosage options, allowing healthcare professionals to customize treatment for patients. Mounjaro is designed for weekly use and targets chronic weight management and Type 2 diabetes.
Jun 26, 2025
Lilly set to introduce Mounjaro pen in India to rival Novo's Wegovy - TradingView
Eli Lilly's Mounjaro has received approval from India's drug regulator for pre-filled injector pens, enhancing its competitive edge against Novo Nordisk's Wegovy. Mounjaro, initially available in vials, will now be offered in six dose strengths of 2.5 mg to 15 mg. This move follows Wegovy's recent launch in India, intensifying the weight-loss drug market.
Jun 26, 2025
Lilly set to introduce Mounjaro pen in India to rival Novo's Wegovy.
Eli Lilly announced that India's drug regulator has approved the launch of pre-filled injector pens for its weight-loss drug, Mounjaro, enhancing its competitive edge against Novo Nordisk's Wegovy. Mounjaro, previously available only in vials, will now be offered in six dose strengths for once-weekly use.
Jun 26, 2025
Mounjaro's pre-filled injection form of Eli Lilly's weight-loss medication has received official approval for ...
Eli Lilly has received approval from India's CDSCO to launch pre-filled injector pens for its weight-loss drug, Mounjaro (Tirzepatide), enhancing its competitive edge against Novo Nordisk's Wegovy. Mounjaro will now be available in six dose strengths for once-weekly use, addressing the rising obesity rates in India, where 254 million people are affected.
Jun 25, 2025
Novo Nordisk Aims for ₹8,600 Crore in Sales in India with Wegovy, a Weight-Loss Medication
Novo Nordisk plans a major expansion in India with its weight-loss drug Wegovy (semaglutide), targeting $1 billion in sales over the next five to seven years. The pan-India launch will feature five strengths and a self-administered delivery system. Despite competition from Eli Lilly’s Mounjaro and patent challenges, Wegovy aims to address India's obesity crisis and improve cardiovascular health.
Jun 25, 2025
Promising Results: Recent findings on a weight loss medication indicate that Eli Lilly is making progress - CNBC
At the American Diabetes Association conference, Eli Lilly showcased promising results for its weight loss pill orforglipron, which helped Type 2 diabetes patients lose 7.6% of body weight. Meanwhile, Novo Nordisk presented data on its CagriSema injection, which combines cagrilintide and semaglutide, showing significant weight loss. Amgen is also advancing its weight loss drug MariTide, focusing on improved dosing strategies.
Jun 25, 2025
Can New Medications Help BMY Mitigate the Effects of Generic Competition? - TradingView
Bristol Myers Squibb (BMY) is focusing on newer drugs like Opdualag, Reblozyl, and Breyanzi to offset revenue declines from legacy products facing generic competition. Sales of Eliquis fell 4% due to Medicare Part D changes. The recent FDA approval of Cobenfy for schizophrenia enhances BMY's portfolio. Despite challenges, BMY's shares have underperformed, trading at a discount compared to industry peers.
Jun 25, 2025
Sales of Prescription Medications Expected to Reach $1.75 Trillion by 2030 Driven by GLP-1s: An Analysis - BioSpace
Total prescription drug sales are projected to reach $1.75 trillion by 2030, with GLP-1 therapies, including Eli Lilly's Mounjaro and Zepbound, expected to account for 9% of prescriptions. Mounjaro could generate $62 billion annually, surpassing AbbVie’s Humira. Novo Nordisk's Wegovy and Ozempic face challenges, while AbbVie’s Skyrizi and Sanofi's Dupixent are also set for significant growth.
Jun 25, 2025
Nektar Announces Positive Phase IIb Results for Rezpeg in Eczema, Yet Analysts Remain Skeptical - BioSpace
Nektar Therapeutics' investigational T cell stimulator, rezpegaldesleukin (rezpeg), showed promise in easing symptoms of atopic dermatitis in the Phase IIb REZOLVE-AD trial, leading to a 175% stock surge. However, analysts raised concerns about its tolerability compared to Dupixent. Nektar plans to present the data at a scientific congress, following a contentious split with former partner Eli Lilly.
Jun 25, 2025
Can the two popular weight loss injections, Wegovy and Mounjaro, help combat obesity rates in India?
Novo Nordisk's Wegovy and Eli Lilly's Mounjaro are now available in India, offering effective injectable therapies for obesity management. Both drugs, semaglutide and tirzepatide, can lead to significant weight loss and improve various health conditions. However, they may cause gastrointestinal side effects and are not suitable for everyone. Caution is advised for use in children and during pregnancy.
Jun 25, 2025
Wegovy, the popular weight loss medication, launches in India with a monthly cost of ₹17,000 - Trak.in
Novo Nordisk has launched its weight loss drug Wegovy, containing semaglutide, in India as a once-a-week injectable therapy, priced between Rs 17,345 and Rs 26,015 per month. This entry into the market complements Eli Lilly’s Mounjaro. Wegovy has shown significant weight loss benefits, but concerns about muscle loss and weight regain persist.
Jun 25, 2025
Wegovy, a highly sought-after medication for weight loss, has been introduced in India. - Hyderabad News
Novo Nordisk has launched its obesity drug Wegovy (semaglutide) in India, targeting adults with obesity or weight-related health issues. Priced between Rs 17,345 and Rs 26,015 per month, Wegovy is a weekly injection that helps users lose about 15% of body weight. The launch precedes the expiration of semaglutide's patent, potentially leading to cheaper generics.
Jun 24, 2025
Novo Ends Partnership with Hims: Weight Loss Agreement Goes Awry Due to Imitation Medications
Novo Nordisk has ended its partnership with Hims & Hers due to concerns over Hims promoting cheaper knock-offs of its weight loss drug, Wegovy. Novo accused Hims of deceptive marketing and violating laws on compounded drugs. Following the announcement, Hims' stock plummeted 34%, while Novo's shares fell over 5%.
Jun 24, 2025
Lilly's trial for its experimental obesity medication withstands examination - Press Telegram
Eli Lilly & Co.'s experimental weight loss pill, orforglipron, demonstrated significant weight loss in Type 2 diabetes patients during a 40-week trial, with no serious side effects reported. The company plans to seek FDA approval for the drug later this year, competing with Novo Nordisk's offerings. Analysts predict a growing market for weight loss medications, potentially reaching $150 billion annually.
Jun 24, 2025
Novo Nordisk Launches $50 Obesity Injection in India - The Battle Against Obesity Intensifies - Yahoo Finance
Novo Nordisk is launching its weight-loss drug Wegovy in India, priced at over $50 per week, significantly lower than U.S. prices. With over 80 million obese individuals in India, the company aims for long-term weight management and cardiovascular risk reduction. As generics from local firms like Sun Pharma loom, Novo is focusing on innovation with next-gen candidates like CagriSema.
Jun 24, 2025
Dr. Ambrish Mithal discusses the introduction of Wegovy in India and its implications for weight-loss and modern medications - India Today.
Novo Nordisk has launched Wegovy, a weight-loss drug containing semaglutide, in India, priced at Rs 4,336 per weekly dose. This injectable medication, designed for long-term use, aims to combat obesity alongside lifestyle changes. Dr. Ambrish Mithal emphasizes that weight loss requires a comprehensive approach, including diet and exercise, while also noting potential side effects like gastrointestinal discomfort.
Jun 24, 2025
Wegovy Debuts in India: Understanding the True Efforts Required for Weight Loss with Modern Medications
Novo Nordisk has launched Wegovy, a weight-loss drug containing semaglutide, in India, priced at Rs 4,336 per weekly dose. This injectable medication aims to aid significant weight loss but is not a standalone solution. Experts emphasize the importance of a comprehensive weight management program, including diet and exercise, alongside medication. Wegovy joins Eli Lilly's Mounjaro in addressing India's obesity crisis.
Jun 24, 2025
Nektar's shares surge as phase 2b eczema study meets its objectives - Fierce Biotech
Nektar Therapeutics reported a successful phase 2 trial for its drug rezpegaldesleukin (rezpeg) in treating atopic dermatitis, leading to a 119% surge in its stock price. The trial showed a 61% improvement in symptoms with the high dose, although it faces competition from Regeneron and Sanofi's Dupixent. Nektar is now preparing for a phase 3 trial.
Jun 24, 2025
Novo Nordisk introduces Wegovy, a weight loss medication, with a monthly cost of ₹17,345 - Mint
Novo Nordisk launched its weight loss drug Wegovy (Semaglutide) in India, ahead of a patent expiry next year. The once-weekly injection is available in five doses, with prices ranging from ₹4,336 to ₹26,015 monthly. The company aims for $1 billion in sales over the next 5-7 years, capitalizing on India's growing $25 billion weight loss market.
Jun 24, 2025
Cigna files lawsuit against Bristol Myers, claiming monopoly on popular cancer medication.
Cigna has filed a lawsuit against Bristol Myers Squibb, alleging violations of U.S. antitrust law. The lawsuit claims that Bristol Myers Squibb has prevented generic versions of its blood cancer drug Pomalyst from entering the market to maintain its monopoly.
Jun 24, 2025
Eli Lilly's Stock (LLY) Soars to New Heights Thanks to Weight-Loss Medication - TipRanks.com
Eli Lilly and Company (LLY) is strengthening its position in the obesity treatment market with its successful drug Zepbound, which generated nearly $5 billion in revenue in 2024. The company is also advancing oral therapies like orforglipron, showing promising results in clinical trials. Analysts project LLY stock could reach $1,000 per share within a year, despite some competitive risks.
Jun 24, 2025
Cigna files lawsuit against Bristol Myers, claiming monopoly on popular cancer medication - CNBC
Cigna Corporation has filed a lawsuit against Bristol Myers Squibb, alleging antitrust violations related to its blood cancer drug Pomalyst (pomalidomide). Cigna claims Bristol Myers' Celgene unit engaged in sham lawsuits and paid off generic drugmakers to maintain a monopoly, resulting in overpayments of hundreds of millions. Cigna seeks unspecified triple damages.
Jun 24, 2025
Nektar's New Eczema Treatment Achieves Trial Objectives, Yet Its Distinction from Dupixent Is Still Uncertain
Nektar Therapeutics' drug, rezpegaldesleukin (rezpeg), has met skin clearance goals in a mid-stage trial for atopic dermatitis, showing significant improvement in patients. However, analysts express concerns about its competitiveness against Sanofi's Dupixent, which demonstrated superior efficacy. Rezpeg's higher rates of injection site reactions may also hinder its market potential. Nektar's stock surged following the announcement, reflecting investor interest.
Jun 24, 2025
Hims & Hers shares drop sharply following the termination of its short-lived collaboration with Novo Nordisk - Business Insider
Hims & Hers stock plummeted 35% after Novo Nordisk ended their partnership due to Hims promoting a cheaper version of Novo's weight loss drug, Wegovy. Novo accused Hims of deceptive marketing and violating laws on compounded drugs. Hims' CEO criticized Novo for anti-competitive practices. Both companies' stocks have fluctuated significantly this year amid ongoing market concerns.
Jun 24, 2025
Viatris Aims at Gilead's Odefsey HIV Success in Europe Following CHMP Endorsement
Jun 24, 2025
Major Pharmaceutical Rivalry: Wegovy Set to Compete with Mounjaro in India's Expanding Weight Loss Medication Sector
Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are set to compete in India's growing weight loss drug market. Mounjaro, launched in March 2025, has gained significant traction, while Wegovy's launch is fast-tracked due to impending patent expiration in 2026. Both drugs belong to the GLP-1 receptor agonist class, with Mounjaro showing potentially superior weight loss results.
Jun 23, 2025
Reasons Behind Today's Decline in Hims & Hers Health Stock - The Globe and Mail
Hims & Hers Health (NYSE: HIMS) shares plummeted 32% after Novo Nordisk ended its partnership, prohibiting the telehealth provider from selling compounded versions of its weight-loss drug, Wegovy. Novo cited legal violations regarding the sale of these compounded drugs. Hims & Hers CEO Andrew Dudum expressed disappointment over the decision, claiming it misleads the public.
Jun 23, 2025
Costs and side effects of the latest blockbuster weight-loss medications detailed | Philstar.com
France has expanded access to weight-loss drugs, allowing all doctors to prescribe Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro. These GLP-1 medications, effective in reducing weight by 15-20%, have revolutionized obesity treatment but come with side effects and high costs. Future developments may yield more effective and convenient options, including Novo Nordisk's experimental drug amycretin.
Jun 23, 2025
Reasons Behind the Decline of Novo Nordisk's Stock Today - The Globe and Mail
Novo Nordisk (NYSE: NVO) shares fell 5.6% after announcing the termination of its partnership with Hims & Hers Health, which previously sold its weight-loss drug, Wegovy. The decline was exacerbated by disappointing trial results for its obesity drug, CagriSema, which achieved only 22.7% weight loss, below the targeted 25%.
Jun 23, 2025
Bayer's Eylea faces potential market decline as Alvotech's biosimilar approaches.
Alvotech has received a positive recommendation from the European Medicines Agency (EMA) for its Eylea (aflibercept) biosimilar, AVT06, indicating a strong likelihood of approval. This follows Bayer's Eylea losing exclusivity in mid-2024, leading to increased competition from other biosimilars. Alvotech aims to enhance patient access to this vital treatment for eye disorders.
Jun 23, 2025
Hims & Hers Shares Drop Following Issues with Weight Loss Medication Agreement - Wall Street Pit
Hims & Hers Health Inc. (HIMS) shares fell 25.41% to $47.90 after Novo Nordisk (NVO) ended direct access to its weight-loss drug Wegovy via NovoCare Pharmacy. This termination disrupts Hims & Hers' growth in the GLP-1 market, which saw a 90% revenue increase in Q3 2024. The move reflects Novo's strategy to control distribution amid competitive pressures.
Jun 23, 2025
Lilly's trial for its experimental obesity medication withstands examination - Medical Xpress
Eli Lilly & Co.'s experimental weight loss pill, orforglipron, demonstrated significant weight loss in type 2 diabetes patients during a 40-week trial, with no serious side effects reported. The results, presented at the American Diabetes Association conference, position orforglipron as a strong competitor against Novo Nordisk's Ozempic. Lilly plans to seek FDA approval for the drug later this year.
Jun 23, 2025
BioNxt Initiates Feasibility Research on Oral Thin Film Formulation of Semaglutide as a Substitute for Injections and Tablets
BioNxt Solutions Inc. has launched a feasibility study to develop an oral dissolvable film formulation of Semaglutide, a GLP-1 receptor agonist marketed as Ozempic®, Rybelsus®, and Wegovy®. This initiative aims to create a non-invasive alternative to current injectable and tablet forms, enhancing patient adherence and comfort. The study is set to begin with the receipt of Semaglutide's active ingredient in July 2025.
Jun 23, 2025
Hims & Hers poised for record decline following the termination of partnership with Novo Nordisk.
Novo Nordisk has terminated its partnership with Hims & Hers, citing concerns over "illegal mass compounding and deceptive marketing" related to the weight-loss drug Wegovy. Hims' stock plummeted 27% following the announcement. The fallout raises the possibility of further legal actions against telehealth companies selling compounded versions of drugs like Wegovy and Eli Lilly's Zepbound.
Jun 23, 2025
Novo unexpectedly terminates partnership for obesity medication with Hims - BioPharma Dive
Novo Nordisk has terminated its marketing deal with Hims & Hers Health for the obesity drug Wegovy, citing legal violations regarding compounded drug sales. Hims had marketed Wegovy during a declared shortage, but the FDA stated the shortage ended in February. Hims CEO Andrew Dudum criticized Novo for misleading the public, leading to a nearly 30% drop in Hims' shares.
